Yuxintong capsule improved anaerobic threshold by 0.86 mL kg/min compared to placebo in patients with stable coronary heart disease after 12 weeks of treatment.
Does Yuxintong capsule improve cardiorespiratory fitness in patients with stable coronary heart disease?
Yuxintong capsule as an adjunctive therapy improved anaerobic threshold and quality of life scores in patients with stable coronary heart disease.
Absolute Event Rate: 0% vs 0%
ETHNOPHARMACOLOGICAL RELEVANCE: Yuxintong capsule, a traditional Chinese patent medicine, has been widely used in the treatment of coronary heart disease (CHD). However, whether it can improve cardiopulmonary fitness (CRF) in patients with CHD remains unclear. AIM OF THE STUDY: To evaluate the efficacy and safety of Yuxintong capsule in CRF in patients with stable CHD. MATERIALS AND METHODS: A multicentre, randomized, double-blind, placebo-controlled, parallel-group trial was conducted in 13 hospitals in China from March 2021 to November 2021, and 404 patients with stable CHD were randomly assigned to receive either Yuxintong capsule and conventional Western medicine (Yuxintong group) or placebo and conventional Western medicine (placebo group) in a 1:1 ratio for 12 weeks (ChiCTR2000041293, December 23, 2020). The primary outcomes were peak oxygen uptake (VO RESULTS: 369 patients, 187 in the Yuxintong group and 182 in the placebo group, were finally included for analysis. Compared with placebo group, 12-week treatment with Yuxintong showed an improvement in AT (0.98 ± 2.88 vs. 0.12 ± 2.79 mL kg CONCLUSIONS: Yuxintong capsule, as an adjunctive therapy to conventional treatment, improved AT, and general health and vitality scores on SF-36 scale in patients with stable CHD. However, the improvements in VO
Zheng et al. (Thu,) reported a other. Yuxintong capsule improved anaerobic threshold by 0.86 mL kg/min compared to placebo in patients with stable coronary heart disease after 12 weeks of treatment.